Microbiotica Celebrates Successful First Year with Third Award Win

Company receives ‘Best Start-up Biotech’ at OBN Awards

Cambridge, UK, 11 October 2017 – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announces that it has been awarded UK Best Start-up Biotech at the OBN Awards, which took place at Oxford Town Hall.

The award recognises Microbiotica’s commercial potential in the fast-growing microbiome space, reflecting its innovative approach to transforming personalised medicine across therapeutic areas through leading microbiome science.

In 2016, Microbiotica was created with £8 million funding from Cambridge Innovation Capital and IP Group to commercialise the ground-breaking research of the Wellcome Trust Sanger Institute.

Mike Romanos, CEO of Microbiotica, said of the win: “We are delighted to have received the recognition of our peers in the UK biotech industry with our third industry award win. We believe this reflects the strength of the science that the Company is based on, the quality of our team and the very rapid progress it has made in the first year.”

The OBN Awards celebrate innovation and outstanding achievement across the UK Life Sciences industry.